Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?

dc.contributor.authorIbáñez, Sebastián
dc.contributor.authorMartínez, Oriela
dc.contributor.authorValenzuela, Francisca
dc.contributor.authorSilva, Francisco
dc.contributor.authorValenzuela, Omar
dc.date.accessioned2021-08-11T14:28:39Z
dc.date.available2021-08-11T14:28:39Z
dc.date.issued2020
dc.description.abstractThe pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.es
dc.format.extent5 p.es
dc.identifier.citationClinical Rheumatology (2020) 39:2461–2465es
dc.identifier.urihttps://doi.org/10.1007/s10067-020-05202-4es
dc.identifier.urihttp://hdl.handle.net/11447/4283
dc.language.isoenes
dc.subjectChloroquinees
dc.subjectCOVID-19es
dc.subjectHydroxychloroquinees
dc.subjectSARS-CoV-2es
dc.titleHydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?es
dc.typeArticlees

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Hydroxychloroquine and chloroquine in COVID-19 should they be used as standard therapy.pdf
Size:
256 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: